by Peter Ciszewski | Dec 19, 2019
The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted unanimously (11 – 0) in favor of approving tazemetostat to treat patients with epithelioid sarcoma. The FDA is scheduled to make its decision for market approval on or...
by Peter Ciszewski | Dec 19, 2019
Tadeusz Robak, MD of the Poznań University of Medical Sciences in Poland provides a summary of a phase II clinical trial assessing rozanolixizumab to treat people with primary immune thrombocytopenia. Rozanolixizumab is an anti-Fc receptor antibody and results...
by Peter Ciszewski | Dec 18, 2019
Timothy Craig, DO of the Penn State Milton S. Hershey Medical Center talks about the need for clinicians to be educated about the pros and cons of entering a clinical trial. Clinical trials, especially those for rare diseases, are excellent opportunities for...
by Peter Ciszewski | Dec 17, 2019
Jonathan Sorof, MD of Global Blood Therapeutics (GBT) explains the mechanism of action of Oxbryta (voxelotor) to treat persons with sickle cell disease. Voxelotor blocks deoxygenated sickle hemoglobin polymerization and attenuates red blood cells from...
by Peter Ciszewski | Dec 16, 2019
Adrian C. Newland, MD, of the Royal London Hospital in London, U.K. provided an update on the Phase 2 clinical trial looking at the safety and efficacy of efgartigimod to treat primary immune thrombocytopenia (ITP). Results of the Phase 2 study were presented...
